Posted by Michael Wonder on 15 Jun 2024
Novavax submits application to US FDA for updated protein based 2024-2025 formula COVID-19 vaccine
14 June 2024 - Novavax's updated JN.1 COVID-19 vaccine is active against current circulating strains, including KP.2 and KP.3.
Novavax today announced that it has submitted an amendment to its Emergency Use Authorisation to the US FDA for its updated JN.1 COVID-19 vaccine (NVX-CoV2705) for individuals aged 12 and older.
